Exclusive: Two Sigma, D.E. Shaw join Wall Street push against US SEC's bid to relax quarterly reporting

Two Sigma Investments, D.E. Shaw, and other Wall Street firms are opposing a proposal that would let public companies opt out of quarterly reporting. The pushback centers on concern that reducing quarterly disclosures would weaken the flow of key financial information to investors. The issue is regulatory in nature and could affect transparency standards, but the near-term market impact appears limited.

Analysis

This is a governance fight with broader market microstructure implications than the headline suggests. Quarterly reporting is one of the few mechanisms that compresses information asymmetry; if optionality expands, the immediate winners are management teams seeking to control disclosure cadence and private-market-style discretion, while the losers are any capital pool that prices on fast earnings revision flow. The second-order effect is likely a higher equity risk premium for smaller-cap and lower-liquidity issuers, where analyst coverage is already thin and a missed quarter can linger for multiple reporting cycles.

The market may initially treat this as a low-probability policy debate, but the real risk is regime creep: even a partial opt-out would create a bifurcated universe where “high-transparency” companies trade at a premium and opaque names trade at a discount, especially in sectors with heavy GAAP-to-cash reconciliation noise. That spread could widen over months as passive flows remain indiscriminate while fundamental capital withdraws from names with weaker disclosure. The biggest tail risk is not the rule itself, but the precedent it sets for further dilution of standardized reporting across public markets.

From a positioning standpoint, this is mildly negative for broad small-cap and high-growth baskets because those cohorts rely most on investor trust and repeated proof points. The catalyst path is slow: policy commentary and rulemaking over months, with sector-level repricing happening earlier if management teams begin signaling support for reduced cadence. The key reversal would be strong bipartisan resistance or explicit exchange-level listing standards that preserve quarterly disclosure even if the SEC relaxes the default.

The contrarian view is that the pushback may actually limit the long-run damage by forcing a clearer market signal around transparency premiums. If the proposal stalls, the episode reinforces the value of frequent reporting and could modestly benefit high-quality compounders versus low-disclosure peers. That makes the setup more attractive as a relative-value rather than outright macro trade.

Key Decisions for Investors

• Go long IWM put spreads 3-6 months out as a hedge against disclosure-risk repricing in small caps; target a modest premium outlay with asymmetric payoff if the debate escalates into concrete rulemaking.
• Pair trade: long quality/transparent large-cap factor exposure (e.g., SPY or QQQ) vs short a small-cap growth basket via IWM or a selected basket of low-cash-flow-visibility names over the next 2-4 months.
• If policy headlines intensify, short the first-order beneficiaries of opacity in high-beta software/biotech where quarterly narrative matters most; use options to cap risk since the policy path is uncertain.
• For long-only portfolios, add to high-disclosure, high-ROIC compounders on any weakness relative to the market; these names should earn a valuation premium if the market starts pricing a transparency spread.
• Maintain a watchlist for exchange-level rebuttals or SEC softening; if the proposal is watered down, cover hedges into the relief rally because the trade could reverse quickly on any explicit preservation of quarterly cadence.